NAII

Business Context and Reporting Period

Company: Natural Alternatives International, Inc. (NAI)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: December 31, 2003 (Six months ended December 31, 2003)
Business Overview: NAI operates primarily in private label contract manufacturing and a direct-to-consumer marketing program. The company manufactures dietary supplements and has operations in the United States and Europe (Natural Alternatives International Europe S.A.).

Key Financial Metrics

Note: All figures in thousands except per share data. Debt includes $85k line of credit, $2.0m term loan, and $714k building loan.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 30% ($7.8 million) year-over-year. Private label contract manufacturing sales grew 35% ($7.3 million), driven by new product sales and volume increases from the two largest customers. Direct-to-consumer sales grew 9% ($441,000).
• Profitability: Net income increased 67% to $1.143 million. Operating income rose 79% to $1.179 million due to higher gross profit ($1.8 million increase) partially offset by increased SG&A expenses ($1.3 million increase).
• Margins: Gross margin remained relatively stable at 23.7% compared to 23.9% in the prior year. The slight decline was attributed to increased material costs and $653,000 in additional inventory reserves for realization risks.
• Cash Flow: Operating cash flow turned negative at $(978,000) compared to positive $1,146,000 in the prior year. This was primarily due to a $4.5 million increase in inventory levels to meet customer requirements and anticipated growth.
• Foreign Exchange: The company recorded a $145,000 foreign exchange gain for the six months ended Dec 31, 2003, compared to a $17,000 loss in the prior year, due to Euro translation.

Guidance, Outlook, and Risks

• Outlook: Management anticipates moderate growth in private label sales but expects a slight to moderate decline in direct-to-consumer sales. Gross margins are expected to improve slightly. SG&A expenses are projected to increase modestly due to incentive compensation.
• Capital Expenditures: Capital expenditures were $1.4 million for the six months ended Dec 31, 2003. Management plans to significantly increase CapEx in the remainder of fiscal 2004 to expand manufacturing capacity (encapsulation, tableting, packaging).
• Debt Refinancing: A $6.5 million credit facility expires on October 24, 2004. Management intends to refinance the facility based on proposals from two lenders. If refinancing fails, the company must repay the outstanding balance from available cash, though they believe they have sufficient liquidity.
• Marketing Strategy: The company is evaluating its marketing plan for the "Dr. Cherry's Pathway to Healing" brand after recent television market expansion did not meet expectations.
• Risks:
  • Customer Concentration: Two customers accounted for 69% of net sales in the six months ended Dec 31, 2003. Loss of either would have a material adverse impact.
  • Supplier Concentration: Reliance on a limited number of raw material suppliers poses a risk.
  • Foreign Currency: A 10% adverse change in exchange rates (Swiss Franc/Euro vs. USD) would decrease earnings by approximately $555,000 for the six-month period.

Investor Verification Checklist

• Verify the status of the credit facility refinancing expected before October 24, 2004.
• Monitor the performance of the "Dr. Cherry's Pathway to Healing" marketing campaign and its impact on direct-to-consumer margins.
• Assess the sustainability of inventory levels ($12.3 million) and the potential for future write-downs given the $653,000 reserve taken in the current period.
• Track the concentration risk associated with the top two customers representing 69% of sales.
• Review the impact of the new lease expansion (42,000 sq ft) and the associated $330,000 letter of credit on future cash flow and credit availability.